Clonal haematopoiesis as a risk factor for therapy-related
myeloid neoplasms in patients with chronic lymphocytic
leukaemia treated with chemo-(immuno)therapy

J 2022

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy

VOSO, Maria-Teresa, Tatjana PANDZIC, Giulia FALCONI, Marija DENCIC-FEKETE, De Bellis ELEONORA et. al.

Základní údaje

Originální název

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy

Autoři

Vydání

British journal of haematology, England, Wiley-Blackwell, 2022, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.500

Kód RIV

RIV/00216224:14110/22:00126416

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/bjh.18129

UT WoS

000767753800001

Klíčová slova anglicky

CHIP and FCR; CLL; t-MN

Štítky

14110323, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 8. 2022 12:37, Mgr. Tereza Miškechová

Anotace

V originále

Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.

Citovat

VOSO, Maria-Teresa, Tatjana PANDZIC, Giulia FALCONI, Marija DENCIC-FEKETE, De Bellis ELEONORA, Lydia SCARFO, Viktor LJUNGSTROM, Michail ISKAS, Del Poeta GIOVANNI, Pamela RANGHETTI, Stamatia LAIDOU, Antonio CRISTIANO, Karla PLEVOVÁ, Silvia IMBERGAMO, Marie ENGVALL, Antonella ZUCCHETTO, Chiara SALVETTI, Francesca R MAURO, Niki STAVROYIANNI, Lucia CAVELIER, Paolo GHIA, Kostas STAMATOPOULOS, Emiliano FABIANI a Panagiotis BALIAKAS. Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. British journal of haematology. England: Wiley-Blackwell, 2022, roč. 198, č. 1, s. 103-113. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.18129.

@article{2211023,
   author = {Voso, MariaandTeresa and Pandzic, Tatjana and Falconi, Giulia and DencicandFekete, Marija and Eleonora, De Bellis and Scarfo, Lydia and Ljungstrom, Viktor and Iskas, Michail and Giovanni, Del Poeta and Ranghetti, Pamela and Laidou, Stamatia and Cristiano, Antonio and Plevová, Karla and Imbergamo, Silvia and Engvall, Marie and Zucchetto, Antonella and Salvetti, Chiara and Mauro, Francesca R and Stavroyianni, Niki and Cavelier, Lucia and Ghia, Paolo and Stamatopoulos, Kostas and Fabiani, Emiliano and Baliakas, Panagiotis},
   article_location = {England},
   article_number = {1},
   doi = {http://dx.doi.org/10.1111/bjh.18129},
   keywords = {CHIP and FCR; CLL; t-MN},
   language = {eng},
   issn = {0007-1048},
   journal = {British journal of haematology},
   title = {Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.18129},
   volume = {198},
   year = {2022}
}

TY  - JOUR
ID  - 2211023
AU  - Voso, Maria-Teresa - Pandzic, Tatjana - Falconi, Giulia - Dencic-Fekete, Marija - Eleonora, De Bellis - Scarfo, Lydia - Ljungstrom, Viktor - Iskas, Michail - Giovanni, Del Poeta - Ranghetti, Pamela - Laidou, Stamatia - Cristiano, Antonio - Plevová, Karla - Imbergamo, Silvia - Engvall, Marie - Zucchetto, Antonella - Salvetti, Chiara - Mauro, Francesca R - Stavroyianni, Niki - Cavelier, Lucia - Ghia, Paolo - Stamatopoulos, Kostas - Fabiani, Emiliano - Baliakas, Panagiotis
PY  - 2022
TI  - Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy
JF  - British journal of haematology
VL  - 198
IS  - 1
SP  - 103-113
EP  - 103-113
PB  - Wiley-Blackwell
SN  - 00071048
KW  - CHIP and FCR
KW  - CLL
KW  - t-MN
UR  - https://onlinelibrary.wiley.com/doi/10.1111/bjh.18129
N2  - Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.
ER  -

VOSO, Maria-Teresa, Tatjana PANDZIC, Giulia FALCONI, Marija DENCIC-FEKETE, De Bellis ELEONORA, Lydia SCARFO, Viktor LJUNGSTROM, Michail ISKAS, Del Poeta GIOVANNI, Pamela RANGHETTI, Stamatia LAIDOU, Antonio CRISTIANO, Karla PLEVOVÁ, Silvia IMBERGAMO, Marie ENGVALL, Antonella ZUCCHETTO, Chiara SALVETTI, Francesca R MAURO, Niki STAVROYIANNI, Lucia CAVELIER, Paolo GHIA, Kostas STAMATOPOULOS, Emiliano FABIANI a Panagiotis BALIAKAS. Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. \textit{British journal of haematology}. England: Wiley-Blackwell, 2022, roč.~198, č.~1, s.~103-113. ISSN~0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.18129.

Podrobný výpis o publikaci